# Aleva Neurotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aleva-neurotherapeutics

- Industry: Medical Devices & Equipment
- Headquarters: Lausanne, Switzerland
- Website: www.aleva-neuro.com
- Total disclosed funding: $36M
- Latest round: Series C (May 27, 2016)
- Investors on record: 7

## About

Aleva Neurotherapeutics SA is a Swiss company focused on developing advanced Deep Brain Stimulation technologies for treating neurological disorders, especially Parkinson's disease and essential tremor.Founded in 2008 in Lausanne, Switzerland, Aleva Neurotherapeutics specializes in innovative solutions for neurological treatments. The company was co-founded by André Mercanzini and Claudio Pollo, with Alain Jordan as CEO. Aleva has successfully raised a total of USD 8.00 mn through various funding rounds, with the latest round being Series E, where they raised USD 8.00 mn.Aleva Neurotherapeutics specializes in the development and commercialization of advanced Deep Brain Stimulation (DBS) technologies aimed at treating neurological disorders, particularly Parkinson’s disease and essential tremor. The company’s flagship product, the directSTIM™ system, employs Directional Deep Brain Stimulation, which allows for precise targeting of brain regions responsible for motor control. This innovative approach is designed to enhance therapeutic benefits while minimizing side effects associated with traditional stimulation methods. Aleva’s technologies are specifically tailored to meet the needs of neurological professionals, including neurologists and neurosurgeons, who are focused on improving patient outcomes. The products are marketed primarily in Europe, with plans to expand into other significant global markets, thereby addressing a wide customer base comprising hospitals, specialized clinics, and healthcare providers.Aleva Neurotherapeutics generates revenue through the sale of its directSTIM™ DBS systems and related components, which are primarily transacted through partnerships with leading neurological clinics and healthcare institutions. The transaction structure typically involves direct sales to hospitals, with potential for ongoing service agreements that include maintenance and support for the systems. Pricing strategies for the directSTIM™ system may involve tiered pricing based on volume purchases or specific institutional agreements, ensuring accessibility and support for healthcare providers. This model supports a business-to-business (B2B) approach, enabling Aleva to focus on building strong relationships with neurologists and neurosurgeons who utilize their technology in clinical settings.Aleva Neurotherapeutics plans to leverage its recent funding of USD 8.00 mn from the Series E round to enhance its product lineup and expand its market presence. Upcoming launches include new iterations of the directSTIM™ system designed for improved patient outcomes. The company is targeting expansion into additional European markets and regions in North America by 2025. Recent developments include Kreos Capital acquiring Aleva Neurotherapeutics SA, which will support these growth initiatives.

## Funding rounds

- Series C, May 27, 2016, $18M — Kreaxi, BioMed Partners, BB Biotech, Wilson Greatbatch Technologies, Inc., Initiative Capital Romandie, Forrestal Capital, Kinled Holding
- Series B, Apr 10, 2012, $4.4M — Kreaxi
- Series A, Aug 25, 2011, $13M — BioMed Partners, BB Biotech, Initiative Capital Romandie

## Investors

- BioMed Partners (https://capitalatlas.ai/funds/biomed-partners) — Series A, Series C
- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series A, Series C
- Initiative Capital Romandie — Series A, Series C
- Kreaxi (https://capitalatlas.ai/funds/kreaxi) — Series B, Series C
- Wilson Greatbatch Technologies, Inc. — Series C
- Forrestal Capital — Series C
- Kinled Holding — Series C